A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus.

Trial Profile

A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Sitagliptin (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2014 Results published in the Drugs and Aging.
    • 02 Oct 2009 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met, according to results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top